Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a global consumer-health company listed on the London Stock Exchange and NYSE, filed this Form 6-K for February 2024. The filing was signed and dated February 2, 2024.
Haleon operates across oral health, pain relief, respiratory health, digestive health, vitamins, minerals and supplements, and other consumer-health categories, with brands including Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum.
Financial and operating metrics
This filing is a director declaration and does not provide revenue, profit, cash flow, margin, debt, liquidity or other financial metrics.
Material changes versus the prior comparable period
There are no reported financial or operating comparisons with a prior period. The material disclosed event is a board appointment involving the Group Chief Executive Officer.
Guidance, outlook, risks and unusual items
Brian McNamara, Haleon’s Group Chief Executive Officer, was appointed as a non-executive director of Mondelēz International, Inc., effective February 1, 2024.
The filing states that there is no further information to disclose under paragraph 9.6.14 of the UK Financial Conduct Authority Listing Rules. No guidance, outlook, risk updates, contingencies or unusual financial items are included.
Investor verification points
- Verify the effective date and terms of Brian McNamara’s Mondelēz board appointment.
- Assess whether the external directorship creates any governance, time-commitment or potential conflict-of-interest considerations.
- Refer to Haleon’s annual report or other filings for current financial performance, leverage, liquidity, guidance and risk disclosures, which are not provided here.